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Abstract
Background: Thromboembolic events are a substantial healthcare concern, both in hospital and community
settings. The current standards of anticoagulation, heparin and warfarin, have well-demonstrated efficacy, but
come with sizeable drawbacks. Heparin requires parenteral administration, and carries the risk of osteoporosis
and severe thrombocyotopenia. Warfarin, the only oral anticoagulant available, gives inconsistent results, and
thus requires frequent laboratory monitoring and adjustment. A fixed-dose oral anticoagulant would ease the
burden of anticoagulation both for patients and prescribers, and would likely increase adherence to
prophylactic guidelines. Dabigatran etexilate, an oral direct thrombin inhibitor, is poised to offer this
advantage, and has been appraised in several diverse settings of thromboembolic risk. While authorized for
use in Europe, it awaits FDA approval in the United States.
Methods: An exhaustive search of available medical literature was performed on five databases: MEDLINE,
CINAHL, ISI World of Science, the National Clinical Trials Registry and the Boehringer Ingelheim Clinical
Trials database, looking for studies comparing this new drug to conventional anticoagulation therapy. Using
the keywords dabigatran, warfarin, heparin, enoxaparin, BIBR 1048 and Pradaxa resulted in 327 entries.
Included for review were original, randomized controlled trials, comparing dabigatran to warfarin or heparin
therapy. Exclusion criteria were: animal studies, non-English language publications, and studies without an
active control.
Results: Of the studies reviewed, seven showed dabigatran to have equal or superior efficacy to various
heparin and warfarin protocols. One study showed dabigatran have inferior efficacy, when compared to
enoxaparin for perioperative anticoagulation. Bleeding rates varied between the trials, but were generally
comparable to control therapy. Among all the trials, two issues arose concerning safety and tolerability;
patients taking dabigatran had a higher rate of dyspepsia in several trials, and one trial demonstrated an
increased rate of myocardial infarction.
Conclusion: Dabigatran stands to offer crucial improvements in anticoagulation therapy. Current studies
show promise, but firm conclusions are limited by several factors in trial design, including variations in control
therapy, minimal long-term studies and a lack of independent investigation. For dabigatran to be established as
an alternative short-term therapy in hospitalized patients, further data is needed comparing it to varying
intensities of parenteral anticoagulation. In regards to its outpatient indications, the ongoing studies of long-
term dabigatran therapy will help to define its safety profile and fortify the efficacy picture demonstrated thus
far.
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Abstract   
 
Background:  Thromboembolic events are a substantial healthcare concern, both in 
hospital and community settings.  The current standards of anticoagulation, heparin and 
warfarin, have well-demonstrated efficacy, but come with sizeable drawbacks. Heparin 
requires parenteral administration, and carries the risk of osteoporosis and severe 
thrombocyotopenia. Warfarin, the only oral anticoagulant available, gives inconsistent 
results, and thus requires frequent laboratory monitoring and adjustment. A fixed-dose 
oral anticoagulant would ease the burden of anticoagulation both for patients and 
prescribers, and would likely increase adherence to prophylactic guidelines. Dabigatran 
etexilate, an oral direct thrombin inhibitor, is poised to offer this advantage, and has been 
appraised in several diverse settings of thromboembolic risk. While authorized for use in 
Europe, it awaits FDA approval in the United States.  
Methods:  An exhaustive search of available medical literature was performed on five 
databases: MEDLINE, CINAHL, ISI World of Science, the National Clinical Trials 
Registry and the Boehringer Ingelheim Clinical Trials database, looking for studies 
comparing this new drug to conventional anticoagulation therapy. Using the keywords 
dabigatran, warfarin, heparin, enoxaparin, BIBR 1048 and Pradaxa resulted in 327 
entries. Included for review were original, randomized controlled trials, comparing 
dabigatran to warfarin or heparin therapy. Exclusion criteria were: animal studies, non-
English language publications, and studies without an active control. 
Results:  Of the studies reviewed, seven showed dabigatran to have equal or superior 
efficacy to various heparin and warfarin protocols. One study showed dabigatran have 
inferior efficacy, when compared to enoxaparin for perioperative anticoagulation. 
Bleeding rates varied between the trials, but were generally comparable to control 
therapy. Among all the trials, two issues arose concerning safety and tolerability; patients 
taking dabigatran had a higher rate of dyspepsia in several trials, and one trial 
demonstrated an increased rate of myocardial infarction.  
Conclusion:  Dabigatran stands to offer crucial improvements in anticoagulation therapy. 
Current studies show promise, but firm conclusions are limited by several factors in trial 
design, including variations in control therapy, minimal long-term studies and a lack of 
independent investigation. For dabigatran to be established as an alternative short-term 
therapy in hospitalized patients, further data is needed comparing it to varying intensities 
of parenteral anticoagulation. In regards to its outpatient indications, the ongoing studies 
of long-term dabigatran therapy will help to define its safety profile and fortify the 
efficacy picture demonstrated thus far. 
Keywords:  dabigatran, enoxaparin, heparin, warfarin, venous thromboembolism, atrial 
fibrillation 
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Oral Dabigatran Etexilate: an Emerging Alternative to Conventional 
Anticoagulation Therapy 
 
BACKGROUND 
 
 Across a variety of healthcare settings, thromboembolic events contribute to 
significant morbidity and mortality worldwide. Among hospitalized patients, venous 
thromboembolism (VTE) has been identified as the most frequent cause of preventable 
death.1 Meanwhile, outpatients with hypercoagulability face a lifelong threat of recurrent 
deep vein thrombosis (DVT), pulmonary embolism (PE) and ischemic stroke. In each 
context, pharmacologic anticoagulation has been proven to reduce these risks 
substantially2-5; however, available therapeutic interventions remain far from ideal. 
Inherent risks and requisite monitoring, closely tied to any anticoagulation plan, place a 
significant burden on patient and practitioner alike, and as a result many patients are 
undertreated.6-10 Surgical patients are discharged with only a few days of VTE 
prophylaxis,10 despite guidelines recommending at least 7-10 days,2 and recent studies 
showing the benefits of even longer therapy.2,11,12 Among outpatients at high risk of 
stroke (those with atrial fibrillation and one or more additional stroke risk factor), less 
than 50% of are prescribed the appropriate anticoagulant therapy.8 This group of patients 
is predicted to grow precipitously in the next 50 years, as the population ages in 
developed countries.13 Given the spectrum and volume of persons at risk, it is clear that a 
new approach in thromboembolism prophylaxis is needed. 
 For the last 50 years, vitamin-K antagonists (VKAs) and heparins have functioned 
as the gold standard of anticoagulation.3,14 Warfarin, an oral vitamin-K antagonist, was 
approved for use in humans in 1954, after functioning successfully for several years as a 
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rat poison.15 Its mechanism of anticoagulation is broad and indirect; warfarin acts by 
decreasing biologically available vitamin K, which in turn prevents the formation of 
coagulation factor II (prothrombin), along with factors VII, IX and X, and regulatory 
proteins C and S.3,14 This non-selective inhibition of four separate clotting factors has 
been postulated to contribute to warfarin’s notoriously steep dose-response curve.16 In its 
favor, warfarin is inexpensive and widely available, with well-demonstrated efficacy.3 
However, warfarin therapy carries a multitude of drawbacks and limitations. Its sharp 
response curve creates a narrow therapeutic index; prescribers must walk a fine line 
between embolic and hemorrhagic events.3 Amplifying this danger is the extreme 
unpredictability of anticoagulation response, both between patients and in the same 
patients over time, as weight, health, and metabolism changes occur.3,17 Multiple dietary 
interactions alter warfarin’s therapeutic activity, including alcohol use and vitamin K 
intake.17 Its metabolism through cytochrome P450 creates a myriad of drug-drug 
interactions.3,17 To compensate for this instability, warfarin therapy entails continual 
laboratory monitoring using international normalized ratio (INR) measurements,3 which 
adds cost, time and inconvenience for its users. Lastly, warfarin can take as many as five 
days of therapy to reach an appropriate degree of anticoagulation, and a faster-acting 
parenteral agent must be given as bridge-therapy on initiation.17 
 Heparin, also an indirect thrombin inhibitor, was discovered early in the 20th 
century, and has been in clinical use since the 1940s.18,19 Heparin molecules enhance the 
function of antithrombin, a plasma protein which acts through several mechanisms to 
inhibit active thrombin.14 Heparin is effective, fast-acting and widely available. However, 
unfractionated heparin (UFH) demonstrates non-specific protein binding and 
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unpredictable distribution, necessitating laboratory monitoring to determine a safe 
dose.14,17,19,20 Additionally, UFH therapy is associated with the serious complication of 
heparin-induced thrombocytopenia (HIT).14,19 Its refined derivative, low-molecular-
weight heparin (LMWH) has the benefit of increased predictability and decreased HIT 
risk,17 but is still difficult to dose in patients with obesity or renal insufficiency.19,20 
Moreover, all heparins require parenteral administration and carry a risk of 
osteoporosis,14 thus decreasing their desirability as long-term therapy.17 
 In the search for a new anticoagulant, several authors have proposed a list of ideal 
properties for such a drug’s kinetics and administration. Cited qualities include: (1) oral 
and parenteral formulations available, (2) a small number of daily administrations 
needed, (3) rapid onset and offset of action, (4) safe and reversible mechanism (5) 
predictable kinetics, (6) wide therapeutic window, (7) minimal interaction with 
concomitant food or drugs, and (8) minimal need for individual monitoring and dose 
adjustment.13,14,17,21  
 Several potential targets for therapy have emerged. Factor Xa and Factor IIa 
(thrombin) are among the most frequently discussed options. Factor Xa inhibitors in 
development include oral rivaroxaban, oral apixaban and parenteral idraparinux.13,14,21  In 
other research laboratories, drugs targeting Factor IIa (thrombin) have shown great 
promise.17 Four intravenous direct thrombin inhibitors (DTIs) have been developed, three 
of which have already been put into use during percutaneous coronary interventions, and 
in the treatment of HIT.22 Ximelagatran, an oral DTI, was developed by AstraZeneca, and 
demonstrated utility in the settings of orthopedic surgery,23 acute VTE therapy,24 stroke 
prevention in atrial fibrillation25,26 and cardioprotection following acute myocardial 
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infarction.27 However, concerns regarding hepatotoxicity and cardiac events during 
clinical trials prompted the FDA to deny approval for the use or marketing of 
ximelagatran in the United States in 2004,20 and it was subsequently withdrawn from all 
markets in February of 2006.13 Since then, dabigatran etexilate, a new oral DTI, has 
entered the later stages of Phase III trials, and is already approved in Europe for VTE 
prophylaxis with orthopedic surgery.20 
 Dabigatran etexilate (hereafter referred to as dabigatran) is an enterally absorbed 
prodrug, which is quickly converted to its active form and widely distributed through the 
body, reaching therapeutic effect within 0.5-2.0 hours after administration.28,29 Dose-
finding studies have demonstrated a serum half-life of 12 to 17 hours and a therapeutic 
effect for 12 to 24 hours following administration.20,29-30 Cytochrome P450 is not 
involved in the metabolism of dabigatran,21 and approximately 80% of the unaltered drug 
is excreted by the kidneys.28  A review of dabigatran administration in seven early trials 
found it to exhibit reliable pharmacokinetics and anticoagulant effect, with no clinically 
significant food or drug interactions evident.20 With this exciting potential for a less 
cumbersome option in oral anticoagulation, Phase III trials were undertaken to study the 
use of dabigatran in several applications.  
 Patients requiring long-term anticoagulation therapy, for indications such as 
secondary VTE prophylaxis and stroke prevention, stand to benefit most from a new oral 
anticoagulant. However, Phase III studies in these arenas necessitate large, lengthy trials 
because the overall rate of embolic events is relatively low.13 On the other hand, a short-
term setting such as perioperative VTE prophylaxis, where thrombus formation rates are 
fairly high and clinical endpoints are more clearly defined, provides a better setting for 
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therapeutic investigation.13,31 Thus, the initial studies on dabigatran focused on its 
potential following knee and hip replacements, where the rate of VTE ranges from 40-
80%,2,11 and a time frame of risk is clearly established.31 Although they focus on a 
specific setting of anticoagulation, these studies have implications for a broad spectrum 
of patients, as Alexander Turpie points out, since the pathophysiology underlying 
thrombus formation is similar between the venous system of surgical patients and the left 
atrium of atrial fibrillation patients.13 On top of the evidence from these initial orthopedic 
surgery trials, in the last six months the results of two major long-term studies were 
released suggesting dabigatran to be effective for acute VTE therapy32 and for stroke 
prevention in atrial fibrillation (SPAF).33 With the extent of information that now exists 
on dabigatran, a thorough review of studies is warranted to synthesize the available 
evidence regarding both the efficacy and safety of this new drug in various 
anticoagulation settings.   
METHODS 
 An exhaustive search of the literature was conducted on three databases: 
MEDLINE, CINAHL, and ISI World of Science, using the following sets of terms: 
“dabigatran and warfarin” and “dabigatran and heparin or enoxaparin.” This resulted in 
approximately 327 entries, including seven original research articles. Adding two 
alternative names for the drug, “BIBR 1048” and “Pradaxa,” yielded several additional 
studies. Further searches were then conducted on the National Institutes of Health (NIH) 
Clinical Trials database and the Boehringer Ingelheim Research & Development website, 
using the keyword “dabigatran,” to uncover any unpublished studies on this new drug. 
This contributed another four completed trials, three of which had posted results. A 
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screening of bibliographic material was then performed for selected works, to provide 
both pertinent background information and evidence of any additional studies that might 
have been missed. 
 For selected articles, inclusion criteria were: original, randomized controlled trials 
(RCTs), comparing dabigatran to either warfarin or heparin therapy. Excluded were non-
English language publications, animal studies, and studies without an active control.  
RESULTS 
In total, this search produced eight studies, looking at dabigatran therapy in three 
different contexts (see Table 1). Given the involved nature of warfarin therapy as a 
comparator, several of the included studies were not double-blinded. For this reason, a 
modified JADAD score was implemented to rate the methodological strength of each 
study (see Table 2). It should be noted that, as these studies involve a drug under 
development, all were sponsored by grants from the manufacturer Boehringer Ingelheim. 
Seven were published articles, and one was an unpublished clinical trial report. 
Four studies examined dabigatran’s application as VTE prophylaxis following 
joint replacement surgery, comparing it to enoxaparin over a perioperative 
anticoagulation period lasting 6-35 days.34-37 The size of these trials ranged from 1949 to 
3463 patients, with VTE occurrence ranging from 6.7% to 40.5%.34-37 These studies were 
all double-blinded, using a combination of identical appearing pills and subcutaneous 
injections in each therapy group. All studies allowed concomitant therapy with low-dose 
aspirin (<160 mg per day) and selective cyclo-oxygenase-2 (COX-2) inhibitors. A 
specified method of venography evaluation, outlined by Rabinov and Paulin,38 was used 
in all trials to assess for DVT at the end of therapy. Changes in liver enzymes were 
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closely monitored in each trial, given dabigatran’s relation to the discontinued 
ximelagatran, as were bleeding rates and other adverse events. All bleeding events in 
these trials were defined as major, clinically significant or minor, based on the criteria 
established by the European Agency for the Evaluation of Medicinal Products39 and the 
investigators of the initial dabigatran study34-37 (see Table 3.) 
The other four studies reviewed compare dabigatran to adjusted-dose warfarin 
therapy; one looked at the treatment of acute VTE32 and three looked at SPAF.28,33,40 
Warfarin was prescribed in each study towards a goal INR of 2.0-3.0. The population in 
these trials ranged from 166 to 18 113 patients, and thromboembolic event rates ranged 
from 0% to 2.7%.28,32,33,40 Two studies followed outcomes over 12 weeks of therapy, one 
over six months, and one over a median of two years treatment. One study was double-
blinded, while the other three employed open-label warfarin.  In addition to embolic 
events, each study looked at bleeding rates, adverse reactions and changes in liver 
enzymes. Definitions of bleeding events in these trials were similar to those in the 
orthopedic surgery trials, but were not based on a single set of guidelines. 
The earliest controlled trial of dabigatran, the Boehringer Ingelheim Study in 
ThROmbosis II (BISTRO II Study),34 earned a modified-JADAD score of six out of 
seven. This European study compared oral dabigatran, in several different dosing 
strategies, to a standard of 40 mg daily subcutaneous enoxaparin following total hip or 
knee replacement surgery. In order to refine the initial pharmacokinetic data and 
determine the appropriate dosing of this new drug, dabigatran groups received 50 mg, 
150 mg or 225 mg twice daily, or 300 mg once daily, and plasma drug concentrations 
were measured over time. Among the 1949 treated subjects, the average age was 65.9 
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years, the average weight was 79 kg, and 79% were female. The mean duration of 
surgery was 1.4 hours, 27% of these using general anesthesia, and 73% using neuraxial 
anesthesia (epidural, spinal, or both). Patients randomized to dabigatran therapy were 
scheduled to begin treatment 1-4 hours post-operatively, with actual delay of 2.6 hours on 
average. Meanwhile, patients randomized to enoxaparin were scheduled to begin 
treatment 12 hours prior to surgery. However, in some countries where the study was 
conducted, standard practice dictates that enoxaparin be started post-operatively,34 and 
this variation was allowed. The primary outcome used for efficacy analysis was the total 
incidence of VTE, based both on symptomatic events and bilateral screening 
venography.34  
The BISTRO II study34 found that dabigatran, in all dose groups higher than 50 
mg, showed statistically superior VTE prophylaxis over enoxaparin (for 150 mg bid, 
ARR of 17.4%, NNT 9; for 225 mg bid, ARR of 15.4%, NNT 7). With only one major 
bleeding event (0.3%), dabigatran 50 mg twice daily showed significantly lower rates 
than all other groups in this respect, including enoxaparin (P= .047). The major bleeding 
rate increased with each escalation in dabigatran dose (4.1% in the 150 mg twice daily 
group, 3.8% in the 225 mg twice daily group, and 4.7% in the 300 mg once daily group), 
but this did not reach statistical significance when compared to the rate of 2.0% among 
enoxaparin users (P= .10, .15, and .051, respectively). Clinically significant bleeding 
occurred in 2.3% to 5.1% of dabigatran users, compared to 2.6% of enoxaparin users. 
Minor bleeding occurred in 4.6% to 9.7% of dabigatran users, compared to 6.4% of 
enoxaparin users.34 
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The authors make it evident that aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels were checked at baseline in every participant, and at 
unspecified intervals thereafter.34 From this data, ALT increases greater than three times 
the upper limit of normal (3 X ULN), occurred in 1.5%-3.1% of the dabigatran groups, 
compared to 7.4% in the enoxaparin group. In regards to other adverse events, the authors 
state that 160 serious adverse events reported during the treatment period, but only 24 of 
these were deemed a potential adverse drug reaction (ADR) by the investigators (0.5% of 
enoxaparin patients, versus 0%, 1.0%, 3.1% and 1.5% of dabigatran 50 mg, 150 mg, 300 
mg and 225 mg, respectively). The specific nature of these events was not commented 
upon.34  
Two years after publishing BISTRO II,34 Eriksson and several of the same 
investigators published the RE-MODEL trial,35 which also meets six of the seven 
modified-JADAD criteria. Examining dabigatran as a perioperative anticoagulant in 2076 
knee arthroplasty patients, the trial was conducted in Europe, Australia and South Africa, 
and focused on two doses of dabigatran (150 or 220 mg once daily) compared to 40 mg 
daily subcutaneous enoxaparin. The mean age among participants was 67.6 years, the 
average weight was 82.3 kg, and 66.0% were female. For the surgical procedure, which 
lasted an average of 91 minutes, general anesthesia was used in 23%, neuraxial 
anesthesia was used in 48%, and a combination of both was used in 29% of cases. 
Dabigatran dosing began 1-4 hours post-operatively, and was initiated with a half-dose; 
the mean time to this starting dose was 3.5 hours. For the control group, enoxaparin 
began either the evening prior to surgery or post-operatively, depending on the local 
standard. Treatment continued 6-10 days until bilateral venography, after which the need 
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for continued anticoagulation was decided by the investigator. For this study, the primary 
efficacy outcome was defined as total VTE events combined with all-cause mortality 
during the treatment period (from the first dose to three days after the last dose).35  
The primary outcome of interest occurred in 40.5%, 36.4% and 37.7% of the 
dabigatran 150 mg, 220 mg and enoxaparin groups, respectively. 35 Per the authors’ 
preset criteria for non-inferiority (a 9.2% margin), both doses of dabigatran proved non-
inferior to enoxaparin, although not superior. Major bleeding rates in the three study arms 
ranged from 1.3% to 1.5%, demonstrating no significant difference between the two 
drugs (P= 1.0 for dabigatran 150 mg and P= .82 for 220 mg). Clinically relevant bleeding 
rates ranged from 5.3% to 6.9%, and minor bleeding occurred in 8.4% to 9.9%. Not all P 
values are provided, but the authors specify that no difference in any bleeding outcome 
between dabigatran and enoxaparin achieved statistical significance.35  
Patients in the RE-MODEL study had liver enzymes measured on four occasions 
between enrollment and a three-month follow-up visit.35 Rates of significant enzyme 
elevation (3 X ULN) appear balanced between the dabigatran 150 mg, 220 mg and 
enoxaparin groups (3.7%, 2.8% and 4.0%, respectively). Blinded analysts screened for 
adverse cardiac events among all participants, and found seven occurrences in the 
dabigatran 150 mg arm (1.0%), three in the 220 mg arm (0.4%) and four in the 
enoxaparin arm (0.6%). Three additional cardiac events occurred during follow-up, one 
in the dabigatran 150 mg group and two in the enoxaparin group.35  
The RE-NOVATE study,36 the third dabigatran trial reviewed, was organized by 
the same primary investigators as the BISTRO II34 and RE-MODEL35 trials, and received 
a validity score of six. Conducted in Europe, Australia and South Africa, this study 
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followed 3463 patients undergoing total hip replacement.36 Among these participants, 
56.9% were female and 2.9% had a history of DVT or PE. The average age was 64.5 
years, while weight and creatinine clearance were 79.3 kg and 90.1 mL/min. Hip 
replacement surgery, lasting a mean of 86.4 minutes, employed solely general anesthesia 
in 26.6%, solely neuraxial anesthesia in 66.5% and a combination of both in 8.6%. 
Dabigatran was given as 150 mg or 220 mg once daily, and was initiated as a half-dose 
one to four hours after surgery (mean 3.4 hours). The control therapy was 40 mg daily 
subcutaneous enoxaparin, starting either the evening prior to surgery or post-operatively, 
based on local standards. In their design, the investigators chose to extend therapy to one 
month (28-35 days), citing several studies and meta-analyses demonstrating the benefit in 
longer anticoagulation,36  most prominently the 2004 American College of Chest 
Physician (ACCP) guidelines.41  
The primary efficacy outcome in the RE-NOVATE study was defined as total 
VTE events plus all-cause mortality during the treatment period.36 Efficacy data was 
analyzed using a pre-defined non-inferiority margin of 7.7%. Among these patients, the 
primary outcome occurred in 8.6% treated with 150 mg dabigatran, 6.0% of those treated 
with 220 mg, and in 6.7% of the enoxaparin group. Based on the 95% confidence 
intervals for these rates, there was no significant difference in efficacy among all groups, 
and the authors state that the criteria for non-inferiority was met.36  
Major bleeding occurred in the 1.6% of the enoxaparin group, compared to 1.3% 
of the dabigatran 150 mg group (P=.6) and 2.0% of the dabigatran 220 mg group (P=.44), 
demonstrating no significant difference between the therapies.36 Clinically relevant and 
minor bleeding rates were distributed similarly among the three groups; the former 
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occurred in 3.5% to 4.7% of patients and the latter occurred in 6.1% to 6.4% of patients. 
P values or confidence intervals are not given for these results, but the authors specify 
that no bleeding outcomes differed between groups with statistical significance.36  
Among RE-NOVATE patients, similar numbers in each group experienced 
adverse events and similar numbers discontinued treatment as a result.36 Seventy-seven 
percent of each group experienced some adverse event. Among these, 8% were deemed 
serious in both dabigatran groups, while 7% were deemed serious among enoxaparin 
users, and discontinuation resulted in 8%, 6% and 6% of the dabigatran 150 mg, 220 mg 
and enoxaparin groups, respectively. The most frequent adverse event was nausea, which 
occurred in 22% of dabigatran 150 mg users, 21% of dabigatran 220 mg users and 25% 
of enoxaparin users (P values not provided). Notable ALT elevation (> 3 X ULN) 
occurred at a significantly higher rate in the enoxaparin group (5% versus 3% in both 
dabigatran groups, P< .01 for both). Acute coronary events were distributed equally 
among the groups, occurring in eight members of the dabigatran 150 mg arm (0.69%), 
five members of the dabigatran 220 mg arm (0.44%) and nine members of the enoxaparin 
arm (0.78%). The enoxaparin group was noted to have three additional cardiac events in 
follow-up. 36  
The RE-MOBILIZE study,37 published two years after RE-MODEL35 and RE-
NOVATE,36 was designed to address the discrepancies in enoxaparin dosing among the 
European trials. Following 2596 patients undergoing total knee replacement (TKR), this 
study was conducted primarily in North America, and used the North American approved 
enoxaparin regimen of 30 mg subcutaneously every 12 hours, starting 12-24 hours post-
operatively.37 Other aspects of the study design remained the same as prior trials, and 
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earned a modified-validity score of six. Among RE-MOBILIZE patients, 57.7% of whom 
were female, the average participant was 66.1 years old, weighed 88 kg, and had a 
creatinine clearance of 82.9 mL/min. Surgery lasted a mean of 90.6 minutes, and general 
anesthesia was used in 52.9%. Spinal anesthesia was used in 46.5% of operations, while 
“other” anesthesia was used in 0.6%. Dabigatran was initiated 6-12 hours after surgery, 
starting with a half dose, and continuing at 150 or 220 mg once daily. Anticoagulation 
continued for 12-15 days (mean of 13 days), citing a 2003 analysis reporting improved 
efficacy of enoxaparin with extended therapy.12 The primary efficacy outcome was 
defined as the total incidence of VTE and death during the treatment period.37  
In RE-MOBILIZE patients, dabigatran could not demonstrate non-inferiority to 
enoxaparin.37 The primary outcome rate in the enoxaparin group was 25.3%. Among 
dabigatran patients, this rate was 33.7% in the 150 mg group and 31.7% in the 220 mg 
group. This data establishes absolute risk reductions of 8.4% (P=.009) and 5.8% 
(P=.0234) when using enoxaparin, compared to the tested doses of dabigatran, with a 
number needed to harm of 12 and 18, respectively. Major bleeding occurred in 0.6% of 
both dabigatran groups, and 1.4% of enoxaparin patients. Clinically relevant bleeding 
occurred in 2.5%, 2.7% and 2.4% of dabigatran 150 mg, 220 mg and enoxaparin patients, 
respectively. Liver enzymes were measured at four points over the course of the study, 
and significant ALT elevations (> 3 X ULN) were rare and distributed evenly among the 
groups (1.0% of dabigatran 150 mg patients, 0.7% of dabigatran 220 mg patients and 
0.9% of enoxaparin patients). The same can be said for serious cardiac events (occurred 
in 0.11%, 0.10% and 0.11%, respectively) during the blinded treatment period. Adverse 
events during follow-up are not specifically delineated.37  
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 While the prior four studies looked at dabigatran as VTE prophylaxis, the RE-
COVER study32 looked at the use of dabigatran in a new context: outpatient therapy 
following the diagnosis of acute venous thromboembolism. The trial was conducted in 29 
countries across the globe, and earned a modified validity score of seven. All of the 2539 
participants had a new, objectively verified DVT or PE, for which six months of 
anticoagulation was deemed appropriate therapy based on risk factors. Among these 
subjects, 41.6% were female and 94.8% were identified as white. The mean age was 54.7 
years, with a weight of 84.9 kg and creatinine clearance of 105.1 mL/min. Nearly five 
percent of the subjects had active cancer and approximately one-quarter had a history of 
prior VTE. Aspirin therapy under 100 mg per day was allowed, but patients requiring 
other anti-platelet therapy were excluded from randomization. Included patients received 
either 150 mg daily dabigatran or adjusted-dose warfarin, following an initial period of 
parenteral anticoagulation with UFH (12.1%), LMWH (90.0%) or fondaparinux (3.4%). 
Double-blinding was maintained through the use of placebo pills in both groups and a 
specially programmed coagulometer that would report true INR values for warfarin 
patients and sham INR values in the dabigatran group. During the monthly follow-up 
visits, warfarin patients were found to be within the correct range 60% of the time, a rate 
noted by the authors to be consistent with good-quality anticoagulation management in a 
2008 community cohort study.9 Therapy continued for six months, barring a serious 
adverse event, with follow-up one month after completion.32 
 To qualify the therapeutic outcomes, baseline imaging of both legs and pulmonary 
arteries was obtained within 72 hours of randomization.32 Later imaging was done based 
on symptomatic indications, and then compared to baseline. The primary endpoint was 
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defined as symptomatic VTE or death associated with VTE, and efficacy was measured 
as the time from randomization to the occurrence of either event. Analysis was carried 
out to demonstrate non-inferiority, with a predetermined margin of 3.6% risk difference. 
Bleeding events were described as major, clinically relevant or nuisance bleeding. Major 
bleeding had to be clinically overt and correlated to a hemoglobin drop of 20 g L-1 or 
greater, a need for transfusion of at least two units red cells, bleeding in a “critical site” or 
fatal bleeding.32 Clinically relevant bleeding met one or more of the following criteria: 
gingival or nasal bleeding lasting over five minutes, spontaneous rectal bleeding 
described as more than spotting, gross hematuria that was either spontaneous or lasted 
over 24 hours, skin hematomas over 25 cm2, bleeding necessitating hospitalization, 
surgical treatment, or a transfusion of under two units blood products or other bleeding 
deemed relevant by the investigator.32  
Upon completion of the treatment period, recurrent VTE or VTE-related death 
was suspected in 134 members of the dabigatran group and 130 members of the warfarin 
group.32 However, a blinded analysis of these cases confirmed the events in only 30 
(2.4%) and 27 (2.1%) patients from each group, respectively. Based on this data, the 
absolute risk reduction was 0.4% in favor of warfarin (95% CI, -0.8 to 1.5). This 
corresponds to a hazard ratio of 1.10 (95% CI, 0.65 to 1.84), which met the study’s 
criteria for non-inferiority in the prevention of recurrent or fatal VTE. When examining 
the study period and the 30-day follow-up together, the primary event rates were 2.7% 
with dabigatran and 2.5% with warfarin, yielding a hazard ratio of 1.05 (95% CI , 0.65 to 
1.70).32 
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Looking at major bleeding events, rates were comparable between the two 
therapies32 (1.6% with dabigatran versus 1.9% with warfarin), yielding a hazard ratio of 
0.82 (95% CI, 0.45 to 1.48). However, the authors do note a substantial difference in risk 
when clinically relevant bleeding events are added in, resulting in composite bleeding 
rates of 5.6% with dabigatran and 8.8% with warfarin (hazard ratio of 0.63; 95% CI, 0.47 
to 0.84; P=.002). Adding in minor bleeding events, the data gives similar results (16.1% 
of dabigatran patients compared to 21.9% of warfarin patients; hazard ratio of 0.71; 95% 
CI, 0.59 to 0.85). The gastrointestinal tract was the one site where bleeding events 
occurred more frequently with dabigatran use (4.2% versus 2.8% with warfarin).32  
The trial lists all adverse reactions reported by at least 3% of subjects,32 and the 
only side effect demonstrating disparity among groups was dyspepsia, which was 
reported in 3.1% of dabigatran patients and only 0.7% of warfarin patients (P <.001). 
Nonetheless, discontinuation rates were significantly higher in the dabigatran group 
(9.0% versus 6.8%; P =.05). Liver-function tests were performed at unspecified intervals, 
and significant ALT elevations (> 3 X ULN) were uncommon and evenly distributed 
between the groups (3.4% versus 3.8% with warfarin; P=.68). Acute coronary syndrome 
occurred in five members of the dabigatran arm (0.4%) and three members of the 
warfarin arm (0.2%), suggesting no increased risk between therapies (P=.73).32 
 The PETRO study28 represents the first trial investigating dabigatran’s efficacy in 
atrial fibrillation and earns a modified-JADAD score of four. PETRO looked at 502 
patients with non-valvular atrial fibrillation and one or more additional risk factors for 
stroke (age over 75 years, prior transient ischemic attack (TIA) or stroke, documented 
coronary artery disease, hypertension requiring medical therapy, diabetes mellitus, 
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symptomatic heart failure or ejection fraction <40%).28 Among the enrolled patients, 18% 
were female, with a mean age of 70 years and median of three stroke risk factors. 
Duration of atrial fibrillation ranged from 0.05 to 30 years, with a median length of 4 
years. At the start of the study, all patients had been on VKA therapy at least eight weeks, 
and had an INR of 2.0-3.0. Weight and creatinine clearance are not specified. An 
additional factor introduced by this study was the concomitant use of aspirin. Subjects 
were randomized into a 3 X 3 factorial distribution to receive either a combination of 
dabigatran (50 mg, 150 mg or 300 mg bid) and aspirin (0, 81 mg or 325 mg daily) or to 
receive adjusted-dose warfarin alone. While the dose of dabigatran was blinded, both 
warfarin and aspirin were open-label. Therapy lasted for 12 weeks, and analysis focused 
on bleeding rates, safety, laboratory changes and any occurrence of cardiovascular or 
peripheral embolic events. Bleeding was categorized as major, clinically relevant or 
nuisance bleeding, with major events defined as: either fatal or life-threatening, or 
occurring in an intracranial, intraocular, intraspinal or retroperitoneal location, or 
associated with a drop in hemoglobin of 2 g L-1 or greater, the need for surgery or 
transfusion of two or more units blood products. Clinically relevant bleeding events 
described: epistaxis or gingival bleeding over five minutes duration, spontaneous rectal 
bleeding, gross hematuria, skin hematoma greater than 25 cm2 size, bleeding resulting in 
hospitalization or the transfusion of under two units blood products, or any other event 
deemed relevant by the investigator. All bleeding events were adjudicated by blinded 
personnel, but the method of evaluation for other outcomes is unspecified.28  
 Within the PETRO treatment period, it became evident that patients taking 600 
mg total daily dabigatran along with aspirin were suffering from major hemorrhage with 
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much greater frequency.28 These patients were consolidated into a single group and 
proceeded to take 300 mg twice daily without aspirin. Five patients receiving lower 
dabigatran doses also discontinued aspirin during the trial. Further changes in dosing 
occurred within the treatment period; investigators decreased dabigatran dosing to once 
daily in 12 patients, based on measurements of creatinine clearance and trough activated 
partial thromboplastin time (aPTT), and these patients were evaluated in their original 
dosing groups. Among patients in the warfarin group, INR was within range 57.2% of the 
time.28 
 Overall there were only two thromboembolic events during the study, both of 
which occurred in patients taking dabigatran 50 mg twice daily (1.96%), one with the use 
of 81 mg of aspirin and one with no aspirin.28 On the other hand, major bleeding events 
only occurred in patients taking 300 mg dabigatran along with aspirin; three events took 
place in patients taking 325 mg of aspirin and one event took place in a patient taking 81 
mg aspirin. With an overall major bleeding rate of 6.3% in the dabigatran 300 mg plus 
aspirin patients, compared to 0% in all other treatment groups, this frequency was 
statistically significant even next to 300 mg dabigatran alone (P <.02). This significance 
persisted when clinically relevant and nuisance bleeding were added in (39.1% for 300 
mg with aspirin compared to 13.3% without aspirin, P=.0003). The other disparity 
determined to have statistical significance was the low rate of total bleeding among the 
50 mg dabigatran patients (regardless of aspirin use) compared to both the warfarin-using 
patients (6.5% versus 17.1%, P=.044) and the higher doses of dabigatran (17.8% for 150 
mg and 21.9% for 300 mg; P of .01 and .0002, respectively). Looking at clinically 
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relevant bleeding events, rates were 1.9% among those taking dabigatran 50 mg, 7.7% 
among both the 150 and 300 mg groups, and 5.7% among those taking warfarin.28 
ALT elevations over three times the upper limit of normal occurred in four 
dabigatran patients (0.9%) and no warfarin patients.28 Acute coronary syndrome was 
observed in two patients, one taking dabigatran 50 mg twice daily and in one taking 
dabigatran 300 mg twice daily, both with 81 mg of aspirin. Additionally, four patients in 
the trial developed congestive heart failure, but the authors found no statistical significant 
underlying either outcome. Overall, 38 patients discontinued treatment, 29 due to adverse 
events. Of the latter group, all were dabigatran users; 4.7% of the 50 mg group, 5.3% of 
the 150 mg group and 8.9% of the 300 mg group stopped treatment because of adverse 
outcomes. The primary ADR was gastrointestinal upset, leading to discontinuation in 1.9-
4.7% of the patients taking dabigatran and none of the warfarin users.28 
The Yamaguchi trial40 was conducted shortly after PETRO,28 but was never 
published. As a small, open-label study, this trial earned a validity score of three out of 
seven points. The study involved 166 Japanese patients with non-valvular atrial 
fibrillation and at least one additional risk factor for thromboembolism (age 75 years or 
older, prior stroke or TIA, hypertension, diabetes mellitus, left-sided heart failure or 
coronary artery disease).40 The actual distribution of ages, comorbidities or other 
medication use among the participants is not given. Comparing 110 mg or 150 mg of 
dabigatran twice daily to adjusted-dose warfarin, the trial looked at outcomes over 12 
weeks of therapy. Patients were randomized but not blinded to which therapy they 
received. Efficacy endpoints included stroke or systemic embolism, TIA, adverse cardiac 
events or death. Safety endpoints included major and minor bleeding events (criteria not 
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given), adverse events and discontinuations. In addition, investigators monitored the 
pharmacokinetics of dabigatran, along with several laboratory values related to 
anticoagulation activity.40  
 During the Yamaguchi trial, no thromboembolic events occurred in the dabigatran 
groups, and one ischemic stroke occurred in the warfarin group.40 In the post-treatment 
period (length unspecified) one ischemic stroke occurred in the dabigatran 150 mg group. 
Major bleeding occurred in 0% and 1.7% of the dabigatran 110 and 150 mg groups, 
respectively, and in 3.2% of the warfarin group. When major and clinically significant 
bleeding were combined, the investigator noted a dose-dependent increase in bleeding 
among dabigatran users, which still remained lower than the warfarin group for both 
doses (4.3% in the dabigatran 110 mg group, 8.6% in the 150 mg group and 11.3% in the 
warfarin group). Looking at total bleeding rates, dabigatran 110 mg and warfarin 
appeared similar (21.7% and 24.2%, while dabigatran 150 mg demonstrated a higher 
incidence (34.5%). The author also reports an increase in major and clinically significant 
bleeding events among patients taking aspirin (rates not given). No risk ratios, confidence 
intervals or P values are provided for Yamaguchi’s results.40  
In regards to other adverse events in the trial, no patient in any group was found 
to have a liver function test (LFT) elevated over twice the upper limit of normal.40 The 
study reports “no serious adverse events related to the investigational drug,” although the 
criteria for this assessment are not specified.40 No information concerning non-serious 
adverse events or discontinuation rates is provided.40  
The final study examined was the RE-LY study (Randomized Evaluation of 
Long-Term Anticoagulation TherapY),33 which compared two doses of dabigatran to 
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warfarin therapy for SPAF over a period of 39 months, and earned a validity score of six 
points. Of the 18 113 individuals enrolled, each had documented atrial fibrillation and 
one or more separate risk factor for stroke (aged 75 years or older, prior TIA or stroke, 
hypertension, diabetes mellitus, coronary artery disease, ejection fraction less than 40% 
or heart failure in the last six months meeting the New York Heart Association class II or 
higher criteria).33 Patients were recruited from 44 different countries, and enrollment was 
directed to include a balanced proportion of patients who were VKA naïve (total lifetime 
use <61 days). Among these enrollees 46.4% were female, with an average age of 71 
years and weight of 82.7 kg. Twenty percent of these patients had history of TIA or 
stroke, while 79.9% reported hypertension and 16.6% had experienced a prior MI. Daily 
aspirin use under 100 mg was permitted, and occurred in approximately 20% of each test 
arm. P values are not given, but the authors specify that all three treatment arms were 
balanced in their baseline characteristics. Patients were randomized to receive either a 
blinded dose of dabigatran (110 or 150 mg twice daily) or open-label warfarin, which 
was dose-adjusted at least monthly. Patients were followed for a median period of two 
years. On conclusion of the study, the average time warfarin patients spent within 
therapeutic range was 64%.33 
 The primary efficacy outcome in RE-LY was defined as stroke or systemic 
embolism during the treatment period.33 Non-inferiority analysis was done to satisfy a 
predetermined relative risk of less than 1.46, when compared to warfarin treatment. Other 
outcomes measured included MI, PE, TIA, hospitalization and death. Bleeding events 
were categorized as major or minor, with a subcategory for life-threatening bleeding. 33,42 
Life-threatening bleeding was defined by: symptomatic intracranial bleeding, a decrease 
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in hemoglobin greater than 50 g L-1, a requirement for surgery, transfusion of four or 
more units of blood products or any inotropic agents, or bleeding that was fatal. Bleeding 
that occurred in a critical area or organ, lead to a drop in hemoglobin of at least 20 g L-1 
or a transfusion of at least two units of blood product constituted major bleeding. All 
other bleeding events were labeled as minor bleeding.33,42 
Based on the RE-LY results, dabigatran 110 mg twice daily was equivalent to 
warfarin for thromboembolic prophylaxis.33 With an event rate of 1.53% per year in this 
group, versus 1.69% per year in the warfarin group, the relative risk with 110 mg 
dabigatran therapy was 0.91 (95% CI, 0.74 to 1.11; P=.34), thus meeting the pre-
specified non-inferiority criteria. Among patients taking 150 mg of dabigatran, the 
prophylactic effect surpassed non-inferiority, and demonstrated superiority to warfarin; 
the primary outcome rate was 1.11% per year, yielding a relative risk of 0.66 with this 
therapy (95% CI, 0.53 to 0.82; P < .001). Bleeding rates also appeared to favor 
dabigatran therapy; major bleeding occurred in 2.71% of the dabigatran 110 mg group 
per year, in 3.11% of the dabigatran 150 mg group per year, and in 3.36% per year 
among warfarin users. This establishes a relative bleeding risk with dabigatran that is 
comparable to warfarin at the 150 mg dose (0.93; 95% CI, 0.81 to 1.07; P=.31) and 
superior to warfarin at 110 mg dose (0.80; 95% CI, 0.69 to 0.93; P =.003). For minor 
bleeding, dabigatran 110 mg established a relative risk of 0.79 versus warfarin (95% CI, 
0.74 to 0.84; P<.001) and dabigatran 150 mg established a relative risk of 0.91 (95% CI, 
0.85 to 0.97; P=.005). For total bleeding events, when compared to warfarin, dabigatran 
110 mg demonstrates a relative risk of 0.78 (95% CI, 0.74 to 0.83; P<.001) and while 
dabigatran 150 shows a relative risk of 0.91 (95% CI, 0.86 to 0.97; P=.002). The 
30 
 
strongest risk reduction is seen in the category of life-threatening bleeding; here 
dabigatran 110 mg yields a relative risk of 0.68 (95% CI, 0.55 to 0.83; P<.001) and 
dabigatran 150 mg a relative risk of 0.81 (95% CI, 0.66 to 0.99; P=.04). Within the 
bleeding results, two clinically important sites of bleeding are sub-categorized: 
intracranial and gastrointestinal. Both dabigatran groups experienced significantly less 
intracranial bleeding (relative risk of 0.31 and 0.40; P < .001 for both comparisons). 
However, patients receiving dabigatran experienced more gastrointestinal bleeding 
(1.12% and 1.51% per year) compared to warfarin (1.02% per year) and this disparity 
reached statistical significance for the higher dabigatran dose (relative risk 1.50; P 
<.001).33 
 RE-LY investigators also looked at hospitalization rates, death rates from vascular 
causes and death rates from any cause.33 In this study, hospitalization rates were lowest in 
the dabigatran 110 mg group (19.4% per year; relative risk of 0.92 compared to warfarin; 
P=.003) while deaths from vascular causes were lowest in the dabigatran 150 mg group 
(relative risk 0.85 versus warfarin; P= .04). Interestingly, the authors describe an 
unexpected finding in the distribution of myocardial infarctions.33 The rate was low 
overall (0.53-0.74%), but occurred more frequently in patients taking dabigatran than 
warfarin. This difference reached statistical significance for the dabigatran 150 mg group 
(relative risk 1.38; 95% CI, 1.00 to 1.91; P =.048). To summarize all these therapeutic 
factors, the investigators designed a “net clinical benefit” value which combined major 
vascular events, major bleeding and death.33 By this measurement, the lower dose of 
dabigatran was equivalent to warfarin anticoagulation, while higher dose dabigatran was 
slightly superior (relative risk of 0.91; P =.04). 
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 Liver function testing was initially conducted on a monthly basis, then every three 
to four months during the later portion of the study.33 Enzyme levels greater than three 
times the upper limit of normal were seen with an equally low frequency among all 
participants (1.9-2.2%). Dyspepsia was the most commonly reported adverse event, and 
the only side effect that occurred more frequently among dabigatran users (11.8% in the 
dabigatran 110 mg group and 11.3% in the 150 mg group versus 5.8% of the warfarin 
group; P<.001 for both comparisons). Discontinuation rates were significantly higher in 
dabigatran users, both at one year of treatment (15% versus 10% with warfarin) and two 
years of treatment (21% versus 17%; P <.001 for both comparisons). Approximately 11% 
of these discontinuations were attributed to gastrointestinal symptoms, while the most 
frequent reason cited was “patient’s decision” (approximately 40% of dabigatran 
discontinuations).33    
DISCUSSION 
The eight trials reviewed outline the exciting potential for dabigatran use in three 
separate indications. Four examined the use of this novel anticoagulant for short-term 
anticoagulation following joint replacement surgery. The other four appraised dabigatran 
for indications requiring long-term treatment (six months to lifetime), although only two 
of these actually continued therapy beyond three months. While further studies are 
needed to flesh out the efficacy of dabigatran in each specific population, looking at these 
early studies together, offers a broad estimate of this new drug’s safety and therapeutic 
value.  
Dabigatran in Orthopedic Surgery 
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A total of four RCT trials have compared dabigatran to enoxaparin for VTE 
prophylaxis following total joint replacement.34-37 Two of these trials found the agents to 
have equal efficacy (RE-MODEL35 and RE-NOVATE36). One trial found dabigatran to 
demonstrate a superior efficacy (BISTRO II34), but it was given in higher doses than 
other trials. The fourth study, RE-MOBILIZE,37 found enoxaparin to have superior 
efficacy, but it was given as delayed, higher-intensity therapy. In terms of bleeding 
events, rates were generally comparable, with the exception of the BISTRO II study, 
where major bleeding rates reached 3.8% to 4.7% with higher dabigatran doses (the 
authors still did not deem this statistically significant compared to enoxaparin therapy).34 
All four studies were designed quite similarly, and share nearly identical strengths and 
limitations. Thus, the discrepancy among these conclusions is best explained by 
variations in the administration of both drugs, combined with possible differences in 
patient population and hospital practice.  
Patient population. All four studies benefited from a large patient population, 
and test groups that were fairly well-balanced in characteristics such as age, weight and 
gender. The average age ranged from 64 to 68 years, with standard deviations near nine 
years.34-37All trials enrolled more female subjects, with a range from 56% to 69% of 
participants. 34-37Average weight was 78-83 kg among the European groups,34-36 and 88 
kg in the North American study.37 Surgical duration and anesthesia type appear balanced 
within each trial, however, it is interesting to note that North American patients (the 
population of the RE-MOBILIZE trial37) underwent general anesthesia at approximately 
twice the rate of patients in the other studies (53%37 versus 24%34-36), while neuraxial 
anesthesia was used in only 46.5% of cases,37 versus 73-78% in the European trials. The 
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resulting disparity among medication use, recovery times and risk of hematoma 
formation could contribute the discrepancy in event rates between the RE-MOBILIZE 
trial and the other three, both for thrombotic and hemorrhagic events.  
Unfortunately, aside from basic demographics, there is little information given 
about the baseline health of the patients involved in these short-term trials. The RE-
MOBILIZE37 and RE-NOVATE36 authors estimate an average creatinine clearance of 83 
and 89 mL/min respectively, but baseline renal function is not given in the BISTRO II34 
and RE-MODEL35 trials. Two to three percent of RE-NOVATE patients had a history of 
DVT or PE,36 but this very relevant risk factor is not specified in other trials. In the initial 
selection of participants, all four studies employed similar exclusion criteria, which does 
provide the groups with some homogeneity. Excluded from all four studies were patients 
with: bleeding diatheses, acute intracranial disease, active malignancy, major surgery, 
trauma, myocardial infarction, uncontrolled hypertension or gastrointestinal bleeding in 
the last three to six months, known liver disease or significant renal insufficiency.34-37 
However, among the medical conditions which were acceptable, including but not limited 
to: heart failure, lung disease, musculoskeletal disease and tobacco dependence, there is 
no way of discerning the distribution within the trial groups. Similarly, all studies 
allowed low-dose aspirin and COX-2 inhibitors, 34-37and one study also allowed the use of 
short-acting non-steroidal anti-inflammatory (NSAID) drugs34; all three of which have 
known cardiovascular interactions, but there is no information regarding the prevalence 
and allotment among participants. Overall, these studies drew from a fairly healthy 
population, as naturally occurs when recruiting patients undergoing elective surgery.31 
This lack of diversity at baseline must be addressed in studies with broader inclusion 
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criteria and better accounting of medical comorbidities before dabigatran is utilized in the 
general hospital population. 
Statistical analysis. All four studies suffer from a loss of efficacy data due to 
incomplete or inconclusive venography.34-37Among treated patients, 21% to 29.5% were 
excluded from primary outcome analysis for this reason. This is apparently a widespread 
problem with venography interpretation, as all authors had taken a predicted 25% loss of 
data into account when sizing their studies. Because of this planning, all data still retained 
90-95% power, as each study had intended.34-37 Nonetheless, the resulting analyses 
cannot truly be labeled as intention-to-treat, and it is possible that some bias is 
introduced.  
Frequency and perioperative timing of administration. Overall, there is a 
remarkable difference in both primary event rates and bleeding rates between the TKR 
patients in the RE-MOBILIZE trial37 and the TKR patients in the European trials.34,35 
Among the latter trials, VTE occurred in 37.7% to 44.6% of patients taking enoxaparin, 
and in 23.7% to 40.5% of patients taking various doses of dabigatran.34,35 Under the RE-
MOBILIZE protocol, a composite outcome of VTE or death occurred in only 25.3% of 
patients on enoxaparin, and in 31.1% to 33.7% of patients taking dabigatran.37 Thus, the 
RE-MOBILIZE data demonstrate a slight decrease in events in the dabigatran arm, and a 
considerable decrease in events in the enoxaparin arm. Looking at bleeding rates, the RE-
MOBILIZE patients also fared better: major bleeding occurred in 0.6% of dabigatran 
patients,37 compared to 1.5% on the same dose in the RE-MODEL study. 35 In addition to 
the anesthesia differences described earlier, the differences in medication dose, frequency 
and treatment length between these trials may underlie the disparity in outcomes. 
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The BISTRO II trial employed 12-hour dosing of dabigatran and 24-hour dosing 
of enoxaparin, and concluded that dabigatran had a superior efficacy with a similar to 
slightly higher bleeding risk.34 The RE-MODEL and RE-NOVATE trials compared 24- 
hour dosing of dabigatran to 24-hour dosing of enoxaparin, and found both the efficacy 
and the bleeding outcomes to be similar.35,36 The RE-MOBILIZE trial compared 24-hour 
dosing of dabigatran to 12- hour dosing of enoxaparin, and found enoxaparin to have 
better efficacy with similar bleeding outcomes.37 This information, in addition to the 
pharmacokinetic studies described earlier,20,29 suggests that dabigatran may be more 
effective when administered twice daily. Likewise, enoxaparin may also be more 
effective when given every 12 hours, as described in the North American protocol.37 
An additional confounding factor is the varied time frames surrounding the first 
dose of each drug, both within and among the four trials. For dabigatran therapy, the 
European trials administered the first dose 1-4 hours post-operatively (average 2.6- 3.6 
hours).34-36 A post hoc analysis performed by the BISTRO II authors showed that VTE 
occurrence was significantly lower when this dose was given within two hours following 
surgery34 (14.1% versus 22.4%, P=.0005). On the other hand, patients in RE-MOBILIZE 
received a first dose of dabigatran 6-12 hours post-operatively (average 9.6 hours37), 
which may have decreased its efficacy. The authors of RE-MOBILIZE minimize this 
potential for difference based on dabigatran’s pharmacokinetic profile,37 but the true 
effect is unclear. 
Enoxaparin administration also varied between protocols. Among the BISTRO 
II,34 RE-MODEL35 and RE-NOVATE36 studies, sites were instructed to begin enoxaparin 
injections the evening prior to surgery, as is common among European guidelines.2 
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However, differences in regional practice led to an array of administration schedules, 
with an average initiation at 14 hours prior to surgery in one trial.35 In the RE-
MOBILIZE study, run by North American investigators, the first dose of enoxaparin was 
always given post-operatively, with an average initiation time of 20 hours following 
surgery.37 The subject of pre- versus post-operative use LMWH has been controversial, 
with varied theories and evidence concerning the ideal balance between efficacy and 
bleeding safety.2 However, a 2002 meta-analysis concluded that there was no significant 
change in VTE or bleeding rate among patients given LMWH 12 hours pre-operatively or 
12-24 hours post-operatively43 and the ACCP guidelines are neutral on the subject.2 Thus, 
it is uncertain if the initial timing of enoxaparin administration represents a substantial 
confounding factor. 
Further complicating the picture with regard to medication administration is the 
length of prophylactic therapy; patients in the RE-MOBILIZE study received 
anticoagulation therapy for an average of 14 days,37 compared to 7-8 days in BISTRO 
II34 and RE-MODEL.35 Current ACCP Guidelines recommend thromboprophylaxis 
following TKR last a minimum of ten days,2 so a trial comparing any new anticoagulant 
to conventional methods would ideally employ this evidence-based standard. However, 
when estimating the therapeutic benefit of dabigatran, it is also important to consider how 
anticoagulation is actually carried out by prescribers and patients. While RE-
MOBILIZE’s intensive, extended therapy meets the current evidence-based guidelines, it 
is far from commonplace in practice, as evidenced by recent analyses.6  As the authors of 
RE-NOVATE36 point out, the average hospital stay is becoming increasingly shorter, and 
many patients do not continue anticoagulation after discharge, so very few patients even 
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reach ten days of therapy.7,10,36 If the option of a fixed-dose, oral anticoagulant existed, 
the chances of achieving post-discharge prophylaxis would undoubtedly increase in 
general practice, and this should be factored into the predictions of dabigatran’s overall 
efficacy.  
Thus, while the four orthopedic surgery trials give conflicting analyses, there are 
clearly multiple areas of disparity, both in methods and overall results. This set of studies 
raises important questions regarding the ideal administration of anticoagulation therapy, 
and further exploration into the dosing of both enoxaparin and dabigatran is warranted. A 
broad conclusion cannot be drawn placing one set of data above another, but local 
practice should be taken into consideration when estimating the efficacy of a new 
therapy.  
Dabigatran in Acute Venous Thromboembolism 
The fifth study discussed, RE-COVER, compared once-daily dosing of dabigatran 
to warfarin therapy, and demonstrated dabigatran to have equivalent efficacy and lower 
total bleeding rates.32 This was based on data from a large, blinded study population. The 
average patient in this study32 was roughly ten years younger than in the joint 
replacement studies,34-37 but new health variables are introduced such as active cancer 
status.32 The baseline characteristics of participants are better delineated than in the 
orthopedic trials, and each appears balanced between the two groups. Unfortunately, 
exclusion criteria are vague in some areas, namely in precluding subjects with “recent 
unstable cardiovascular disease,” a broad characterization which includes a large number 
of patients potentially requiring anticoagulation therapy.32  
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In terms of analysis, the trial is quite thorough, with 99% of the randomized 
patients included in the final outcomes assessment.32 The authors note that their figures 
represent a modified intention-to-treat approach, as they excluded a group of 25 patients 
who never received a dose of either drug following randomization.32 From that point 
forward however, all patients were analyzed in their appropriate groups, with the 
endpoints being either completion of six months therapy or 6 days from the final dose of 
a discontinued drug.32 
One limitation of the study, in comparison to the orthopedic trials, is a low overall 
rate of measurable events, although the study was still sized for statistical significance.32 
This is a product of both the lower risk of VTE outside of the surgical setting13,31 and the 
study’s method of screening only symptomatic patients. At the point of efficacy analysis, 
there may have been asymptomatic thromboses, placing the patient at risk for adverse 
outcomes in the future. Repeating the vascular imaging in every patient on completion of 
therapy in the RE-COVER study32 would have allowed a more complete picture of 
therapeutic effect. 
As in the orthopedic trials, it should be noted that a drug’s efficacy may differ 
between a clinical study and real-life practice, particularly for warfarin, as it requires 
such close monitoring and frequent follow-up. However, even with the structured 
regimen of the RE-COVER trial, INRs were only within range 60% of the time.32 This is 
consistent with a 2008 community-based cohort study, which found that the average time 
warfarin users spent within therapeutic INR range was 66.5%.9,32 Thus, for the typical 
warfarin user, the data from RE-COVER are quite applicable. However, one-third of 
patients in this community analysis were within range less than 60% of the time.9 For 
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these patients with poor control on warfarin therapy, dabigatran would offer a greater 
reduction in both thrombotic and hemorrhagic events than indicated by these results.  
Dabigatran in Atrial Fibrillation 
 Among the three studies investigating dabigatran’s value for stroke prevention in 
atrial fibrillation,28,33,40 only one offers statistical evidence of efficacy.33 The other two, 
because of their small size and short duration of therapy, cannot provide meaningful data 
for embolic events.28,40 However, all three trials offer varied degrees of insight regarding 
the safety and tolerability of dabigatran.  
Patient population. All patients in these studies had documented non-valvular 
atrial fibrillation, plus one or more separate risk factor for stroke.28,33,40 This criteria 
parallels the definition of patients for whom VKA therapy is recommended, per 
evidence-based guidelines.5 The average patient in the PETRO28 and RE-LY33 studies 
was 70 and 71 years old, respectively, while the Yamaguchi trial40 did not report any 
baseline characteristics. Among the former trials, hypertension was seen in the majority 
of patients (67%-74% in PETRO28 and 79% in RE-LY33). In both, diabetes mellitus was 
present in about one-fourth of participants and heart failure in one-third.28,33 Patients in 
the PETRO study had a median of three risk factors for stroke,28 while the RE-LY study33 
reported a mean CHADS2*
                                                 
* CHADS2 score reflects a composite risk of stroke, based on factors of congestive heart failure, 
hypertension, age > 75 years, and diabetes mellitus (all one point) and history of prior stroke or TIA (two 
points)44  
 score of 2.1. When compared to the baseline characteristics 
provided by the orthopedic and acute VTE trials,32,34-37 both PETRO28 and RE-LY33 
appear to utilize an older population with more cardiac risk factors. This is fitting, 
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considering the therapeutic group it aims to address, and it is something that should be 
considered when viewing the disparity in adverse cardiac events.  
Yamaguchi trial. Due to a combination of size and design limitation, this study 
offers the least reliable data concerning dabigatran. Drug administration was open-label, 
with no specified protocol to avoid bias in the process of reporting and evaluating 
endpoints.40 No information was given describing the randomization process or the 
baseline characteristics between groups, leaving out critical details such as history of 
prior stroke or exposure to warfarin. The short duration of therapy, small population size 
and low frequency of primary outcomes provide little insight into the efficacy of long-
term treatment with dabigatran. However, the study does provide limited evidence that 
dabigatran appears safe in the Japanese population (patients of Asian descent have 
compromised only a small portion of dabigatran studies to date) with a bleeding profile 
similar to adjusted-dose warfarin.40  
PETRO. Like the Yamaguchi trial, PETRO28 suffers from a small size, short 
duration and several design flaws. With a few exceptions, no events in the PETRO study 
occurred with enough frequency to establish statistical import. Moreover, the 
stratification into so many dose groups with the additional variable of aspirin use makes 
these trends even harder to interpret. The safety of aspirin is certainly an important 
question for the population of patients with atrial fibrillation, but would have been better 
addressed in a later stage trial, when the optimum doses of dabigatran had been 
established. When interpreting the PETRO results, it should be noted that patients were 
taking anywhere from one-third to two times the total daily dabigatran dose that was used 
in later trials of long term use (50 – 600 mg daily in PETRO28 versus 150 - 300 mg daily 
41 
 
in RE-COVER32 and RE-LY33). Another confounding factor was the use of warfarin 
prior to the trial period; all randomized patients had been on warfarin therapy for eight 
weeks or longer at the start of therapy, and had already achieved a therapeutic INR.28 
This creates what has been termed a “survivor bias,” as only patients with a longer-
established atrial fibrillation, who tolerated warfarin therapy in the past are included.42,45 
Given these factors of size and bias, the PETRO28 study does not provide reliable data 
concerning the efficacy of dabigatran for stroke prevention and offers only minimal 
insight regarding the safety and bleeding profile. From this trial, 361 dabigatran patients 
were rolled over into a long-term extension trial (PETRO-Ex) with an average of 29 
months follow-up.46 However, as this study was neither randomized nor controlled, it 
could not be included for review.  
RE-LY. With its large population, extended therapeutic exposure, and well-
organized structure, the results of RE-LY33 offer the best evidence thus far concerning the 
efficacy and safety of dabigatran as an anticoagulant. Among the 18 113 participants, half 
were warfarin naïve- thus eliminating the potential of survivor bias.33,42 At baseline, 
groups were balanced and well-described in terms of age, gender, comorbidities and 
medication use. Follow-up was complete in 99.9% of patients and intention-to-treat 
analysis was used.33 One potential weakness in the RE-LY design is the non-blinded 
administration of the control drug, warfarin. However, the susceptibility to bias seems 
small since the primary outcomes of interest were measured clinical events, all of which 
were adjudicated by blinded panels. Nonetheless, bias could have factored into the more 
subjective phenomenon of ADRs for this new drug. Additionally, a reporting bias among 
patients or staff could have influenced the outcome measurements. Towards this end, the 
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authors argue that the balance of adverse outcomes reported in the study for both drugs 
(bleeding, myocardial infarction and discontinuation) diminishes the likelihood of a bias 
in either direction.33 When looking at bleeding rates in the RE-LY data33, it should be 
noted that the category of “minor bleeding” in this trial encompasses a range of events 
that were differentiated as “clinically significant” and “minor” or “nuisance bleeding” in 
other trials.28,32,34-37 However, the criteria for major bleeding were the same as in other 
non-surgical trials.28,32 Overall, the RE-LY33 study provides valuable evidence for the 
therapeutic value of dabigatran in patients with atrial fibrillation. It is the largest and most 
comprehensive of all eight trials reviewed. However, given the monumental change it 
suggests in moving away from a 60 year old therapy, additional trials are needed to verify 
RE-LY’s results. 
Safety and Adverse Drug Reactions 
 Valuable safety and tolerability information can be gleaned, to varying extents, 
from all the included trials. With six studies examining dabigatran therapy for up to 12 
weeks, trials thus far have demonstrated the short-term safety of this drug in a fairly 
diverse population. Unfortunately, only two studies have investigated longer-term 
therapy, and safety in this setting remains a concern. 
Hepatotoxicity. Liver damage was a major concern for direct thrombin inhibitors, 
following on the heels of ximelagatran’s FDA rejection. However, every study reviewed 
here demonstrates no hepatotoxicity attributable to dabigatran.28,32,33-37,40  
Tolerability. Several studies demonstrated a higher discontinuation rate among 
patients assigned to dabigatran.32,33,36,37 Part of this can be attributed to the survivor bias 
among patients with prior exposure to warfarin or enoxaparin, however, part of the 
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discontinuation was certainly related to gastrointestinal upset, which was a well-
demonstrated side effect in many trials.28,32,33,36   
Bleeding. Among the trials comparing dabigatran to enoxaparin, the rates of total 
bleeding were equivalent.34-37 On the other hand, in trials with warfarin as control 
therapy, dabigatran appeared to have a superior bleeding profile,32,33,40 with the exception 
of PETRO patients taking high dose dabigatran and concomitant aspirin.28 The increased 
risk of gastrointestinal bleeding with long-term dabigatran therapy, as demonstrated in 
both the RE-COVER and RE-LY studies,32,33 is certainly concerning. However, 
dabigatran also demonstrated one-third the rate intracranial bleeding seen in warfarin 
users,33 which should also be factored into any risk-benefit analysis.  
Acute Coronary Events. Myocardial infarction (MI) is an obvious concern 
among patients at thromboembolic risk. Thus, the findings of increased MI occurrence 
among dabigatran users in the RE-LY study33 demands further investigation. Among the 
other seven trials, each reported occurrences of acute coronary syndrome, and no 
apparent trend emerged. However, RE-LY patients had a much longer exposure to 
dabigatran than any other study. One theory proposed by the authors is that warfarin has a 
proven cardioprotective effect which dabigatran may lack.33 Slightly increased rates of 
non-fatal MI were also noted among ximelagatran users, in pooled data from trials 
investigating its use with knee replacement.47 On the other hand, ximelagatran was 
specifically investigated as a potential cardioprotective post-MI therapy in combination 
with aspirin, and was found to have a beneficial cardiac effect in this trial.27,47 When 
considering the bigger picture of risks and benefits, it should be noted that even with the 
higher rate of MI in the RE-LY trial, dabigatran patients still had an overall rate of death 
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from vascular causes that was equal to warfarin patients in the 110 mg dose group and 
lower than warfarin patients in the 150 mg dose group.33 Clearly, further studies and sub-
group analyses are needed to parcel out the factors underlying this adverse event. 
Limitations of Study  
The trials reviewed encompass a wide variety of health care settings and a 
spectrum of anticoagulation intensity. This was done in order to gather the most data 
available regarding dabigatran’s general safety, while considering several potential 
indications for its use. While there are physiologic similarities to thrombus formation in 
all settings,19 as described earlier, the baseline characteristics of these patients vary 
greatly, and one study result cannot be simply generalized for dabigatran use in another 
setting.  
Furthermore, as a new pharmaceutical product, current studies of dabigatran are 
limited by a lack of experience and exposure. Three of the included trials were designed 
more for the purposes of dose-finding than efficacy analysis,28,34,40 and therefore lack the 
appropriate size or length of exposure to establish a true therapeutic comparison to 
warfarin use. Additionally, a limited number of investigators have conducted these trials, 
all of which were financially supported by the drug manufacturer Boehringer Ingelheim. 
Several of the primary investigators in every published study disclose a financial 
relationship to this company, either as an employee or a consultant.28,32-37 Although the 
variety of both beneficial and adverse outcomes disclosed in these clinical trials suggests 
a certain degree of fairness in reporting, this potential bias cannot be completely ignored.  
Publication bias was minimized by reviewing the NIH clinical trials registry and 
the Boehringer Ingelheim clinical trial records for unpublished studies. However, the 
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information posted on such sites is not as complete or well-reviewed as published 
articles, and thus the one study this yielded40 is not as reliable. In addition, there was a 
fourth Phase III trial listed as completed on the NIH website, but no records were 
available on the pharmaceutical website (National Clinical Trial ID 00657150). Whether 
the results of this trial would contradict the efficacy suggested by other trials cannot be 
known. 
Future Research and Development 
 For dabigatran’s application to surgical patients, further studies are needed 
comparing dabigatran to varying intensities of enoxaparin therapy as well to 
fondaparinux, a parenteral anticoagulant with emerging value over enoxaparin.20 Such 
evidence would help streamline the confusing array of local perioperative protocols, and 
would more clearly establish where dabigatran may fit into this spectrum of guidelines. 
Even if higher intensity parenteral therapy proves more efficacious, dabigatran could still 
improve post-operative outcomes by offering a fixed-dose, oral medication for outpatient 
use. This would allow patients to easily continue anticoagulation therapy for a month 
after orthopedic surgery, and thus achieve the fullest possible VTE prophylaxis. 
 When considering acute VTE, dabigatran stands as a potential therapy for both 
immediate therapy and secondary prophylaxis. One study has already demonstrated 
efficacy in the former context, when combined with an initial period of parenteral 
anticoagulation.33 A long-term study examining secondary prevention of VTE, RE-
MEDY, has been underway since 2008,20 and will offer valuable data regarding both the 
efficacy of dabigatran in this setting, and its safety for long-term use.  
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One exciting potential that was not addressed by any study is the use of 
dabigatran as monotherapy for acute VTE. Based on its known mechanism of direct 
thrombin inhibition, it is postulated that dabigatran may be able to inhibit fibrin 
production by both free and clot-bound thrombin, a characteristic that distinguishes it 
from members of heparin family.20 This increased anticoagulation activity, combined 
with a short time to therapeutic onset, could eliminate the need for initial parenteral 
anticoagulation, which is a routine addition to warfarin therapy that adds to inpatient 
time, cost and inconvenience.20,32 
 Stroke prevention in atrial fibrillation is perhaps the most promising venue for this 
new drug, as these patients usually require indefinite anticoagulation, and have no 
alternative to warfarin for oral therapy. However, only one statistically robust study 
currently supports dabigatran use in this setting.33 Further studies are indicated to better 
understand the safety of this drug in long-term use, exploring how it interacts with 
various cardiovascular risk factors and concomitant medications.  
One factor not addressed by these studies, but important to every patient and 
clinician, is cost of therapy. Wolowacz et al performed a cost-effectiveness analysis 
comparing dabigatran and enoxaparin, based on the data from Phase III trials in knee 
replacement patients, and concluded that dabigatran was cost-saving, primarily through 
lower administration costs.48 However, the price difference between dabigatran and 
warfarin is much greater; one author estimated a month of dabigatran to cost ten times 
what warfarin therapy would, including monitoring.49 Dabigatran will likely not be an 
option for all patients initially because of these monetary issues, nonetheless, if oral 
thrombin inhibitors promote better compliance with anticoagulation guidelines, both by 
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patients and providers, they have the potential to greatly reduce thromboembolic 
morbidity and mortality, and thus lower healthcare costs over time. 
CONCLUSION 
Decisions surrounding anticoagulation are difficult for patients and clinicians 
alike. Overall compliance with evidence-based guidelines is poor, in both hospital and 
community settings. 6-10 This is likely due to the risks and inconveniences associated with 
conventional therapy. As the first new oral anticoagulant in over 50 years, dabigatran 
etexilate stands to provide substantial improvements in both the ease and safety of 
outpatient anticoagulation. Further data regarding the cardiovascular safety of dabigatran 
will likely emerge in the next few years, and it may not prove to be the optimal therapy 
for all patients. However, millions of patients at thromboembolic risk stand to benefit 
from this long awaited alternative to warfarin, and every clinician should be tuned into its 
progress as the Phase III trials come to an end.  
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TABLES 
Table 1. Characteristics of Included Studies 
STUDY/ 
AUTHOR/ 
YEAR 
PUBLISHED 
STUDY 
TYPE/ 
LOCATION 
PATIENT 
NO.¶/ 
POPULATION 
INTERVENTION COMPARISON OUTCOMES VALIDITY 
SCORE 
COMMENTS 
BISTRO II34/ 
Eriksson et al/ 
2005 
Double-
blinded RCT/ 
multi-center 
dose-finding 
study in 
Europe and 
South Africa  
1949/ Pts 
undergoing total 
hip or knee 
replacement 
Dabigatran 50, 150 
or 225 mg bid, or 
300 mg qd, starting 
1-4 hours post-op, 
continuing 6-10 
days 
Enoxaparin 40 
mg daily, starting 
night before 
surgery and 
continuing for 6-
10 days 
VTE, bleeding 
events, adverse 
events, 
pharmacokinetic 
parameters 
6/7 Loss of 24%-
25% of treated 
patients in 
efficacy 
analysis 
RE-
MODEL35/ 
Eriksson et al/ 
2007 
Double-
blinded RCT/ 
multi-center 
in Europe, 
Australia and 
South Africa 
2076/ Pts 
undergoing total 
knee 
replacement 
Dabigatran 150 or 
220 mg qd, starting 
with ½ dose 1-4 
hours post-op, 
continuing 6-10 
days 
Enoxaparin 40 
mg qd starting 
evening prior to 
surgery, 
continuing 6-10 
days 
VTE + all-cause 
mortality, bleeding 
events, liver 
function, adverse 
events 
6/7 Loss of 25%-
26% of treated 
patients in 
efficacy 
analysis 
RE-
NOVATE36/ 
Eriksson et al/ 
2007 
Double-
blinded RCT/ 
multi-center 
in Europe, 
Australia and 
South Africa 
3463/ Pts 
undergoing total 
hip replacement 
Dabigatran 150 or 
220 mg qd, starting 
with ½ dose 1-4 
hours post-op, cont. 
28-35 days 
Enoxaparin 40 
mg qd starting 
evening before 
surgery, 
continuing 28-35 
days 
VTE + all-cause 
mortality, bleeding 
events, liver 
function, adverse 
events 
6/7 Loss of 22-25% 
of treated 
patients in 
efficacy 
analysis 
RE-
MOBILIZE37/ 
Ginsberg et al/ 
2009 
Double-
blinded RCT/ 
multi-center 
in North 
America 
2596/ Pts 
undergoing total 
knee 
replacement 
Dabigatran 150 or 
220 mg qd, starting 
with ½ dose 6-12 
hours post-op, cont. 
12-15 days 
Enoxaparin 30 
mg bid, starting 
12-24 hours post-
op, cont. 12-15 
days 
VTE + all-cause 
mortality, bleeding 
events, liver 
function, adverse 
events 
6/7 Loss of 26%-
30% of treated 
patients in 
efficacy 
analysis 
RE-
COVER32/ 
Schulman et 
al/ 2009 
 
Double-
blinded RCT, 
multi-center, 
29 countries  
2539/ Pts with 
acute, 
symptomatic 
VTE 
Dabigatran 150 mg 
bid for 6 months, 
following initial 
parenteral 
anticoagulation 
Warfarin adjusted 
towards an INR 
of 2.0-3.0 for 6 
months, 
following initial 
parenteral 
anticoagulation 
Time to symptomatic 
VTE or death, 
bleeding events, liver 
function, adverse 
events 
7/7 All patients had 
a mean of 10 
days initial 
parenteral 
anticoagulation 
with UFH, 
LMWH or 
fondaparinux 
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Table 1 (continued). Characteristics of Included Studies  
STUDY/ 
AUTHOR/ 
YEAR 
PUBLISHED 
STUDY 
TYPE/ 
LOCATION 
PATIENT 
NO.¶/ 
POPULATION 
INTERVENTION COMPARISON OUTCOMES VALIDITY 
SCORE 
COMMENTS 
PETRO28/  
Ezekowitz et 
al/ 2007 
Partially 
blinded RCT, 
multi-center, 
dose-finding 
study in 
Europe and 
United States 
502/ Pts with AF 
and 1 or more 
additional stroke 
risk factor 
Dabigatran 50, 150 
or 300 mg bid plus 
0, 81 or 325 mg 
aspirin for 12 weeks  
Warfarin alone, 
adjusted towards 
INR of 2.0-3.0 
for 12 weeks 
Cardiovascular or 
peripheral embolic 
events, bleeding 
events, adverse 
events, laboratory 
changes 
4/7 
 
 
 
Small size; 
incomplete 
blinding; 
unclear method 
of adjudication 
for non-
bleeding events 
Yamaguchi40/ 
2007 
(unpublished) 
Open-label 
RCT, multi-
center, dose-
finding study 
in Japan 
166/Pts with AF 
and 1 or more 
additional stroke 
risk factor  
Dabigatran 110 or 
150 mg bid for 12 
weeks 
Warfarin adjusted 
towards an INR 
of 2.0-3.0 (1.6-
2.6 in patients 
aged 70+) for 12 
weeks  
Stroke, TIA, 
systemic embolism, 
MI, adverse events, 
bleeding events, 
laboratory changes 
3/7 Small size; 
randomization 
or baseline 
characteristics 
not described; 
open-label 
therapy; 
unclear method 
of adjudication 
RE-LY33/  
Connolly et al/ 
2009 
Partially 
blinded RCT, 
multi-center, 
44 countries 
18 113/ Pts with 
AF and 1 or 
more additional 
stroke risk factor 
Dabigatran 110 or 
150 mg bid, 
continuing for a 
median of 2.0 years 
Warfarin adjusted 
towards an INR 
of 2.0-3.0, 
continuing for a 
median of 2.0 
years. 
Stroke or systemic 
embolic event, 
bleeding events, all-
cause mortality, 
hospitalization, 
myocardial 
infarction, liver 
function, adverse 
events 
6/7 
 
Incomplete 
blinding 
AF=atrial fibrillation; bid=twice daily; qd=once daily 
¶ Indicates the number of patients receiving one or more dose of study drug 
 
 
 
 
58 
 
Table 2. Components of Modified-JADAD Scoring 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Perioperative Bleeding Event Definitions34,39 
MAJOR BLEEDING CLINICALLY SIGNIFICANT BLEEDING 
Retroperitoneal bleeding Gingival bleeding or epistaxis > 5 minutes duration 
Intracranial bleeding Spontaneous rectal bleeding 
Intraocular bleeding Spontaneous gross hematuria 
Intraspinal bleeding Intervention-related hematuria lasting >24 hours 
Clinically overt bleeding leading to: Spontaneous skin hematoma > 25 cm2 
          > 20 g L-1 decrease in hemoglobin level Wound hematoma > 100 cm2  
          Transfusion of > 2 units of blood product Other bleeding deemed significant by the investigators 
          Treatment cessation  
          Re-operation  
          Death  
Criteria used in orthopedic surgery trials34-37 
All bleeding events not meeting one of the above qualifications were described as minor bleeding  
 
 
 
 
 
 
CRITERIA POINTS AWARDED 
Study size > 1000 patients? Yes……………1 No/cannot tell……0 
Was the study described as random? Yes……………1 No/cannot tell……0 
Was the randomization scheme described and appropriate? Yes……………1 No/cannot tell……0 
Was the study described as double-blind? Yes……………1 No/cannot tell……0 
Were all the outcome evaluators blinded to treatment group? Yes……………1 No/cannot tell……0 
Was there a description of dropouts and withdrawals? Yes……………1 No/cannot tell……0 
Was intention-to-treat analysis used? Yes……………1 No/cannot tell……0 
STUDY/SETTING DABIGATRAN OUTCOMES      
% (95% CI) 
ENOXAPARIN OUTCOMES    
% (95% CI) 
ADVERSE EVENTS COMMENTS 
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Table 4. Summary of Outcomes 
 
 
BISTRO II34/ 
VTE prophylaxis 
following TKR or 
THR 
VTE 
50 mg bid       28.5 (23.5-33.9) 
150 mg bid     17.4 (13.1-22.3) 
300 mg qd      16.6 (12.5-21.5) 
225 mg bid     13.1 (9.5-17.5) 
Major bleeding 
50 mg bid       0.3 (0.0-1.4) 
150 mg bid     4.1 (2.4-6.6) 
300 mg qd      4.7 (2.8-7.3) 
225 mg bid     3.8 (2.2-6.2) 
VTE 
40 mg qd     24.0 (19.3-29.2) 
 
 
 
Major bleeding 
40 mg qd     2.0 (0.9-4.0) 
24 serious adverse events deemed 
attributable to medication. 
Definitions and distribution not 
provided 
 
 
 
~Therapy length 6-10 days 
~Enoxaparin started pre-operatively 
in most patients, while dabigatran 
was started post-operatively 
RE-MODEL35/ 
VTE prophylaxis 
following TKR  
VTE + all-cause mortality 
150 mg qd     40.5 (36.3-44.7) 
220 mg qd     36.4 (32.2-40.6) 
 
Major bleeding 
150 mg qd     1.3 (0.6-2.4) 
220 mg qd     1.5 (0.7-2.7) 
 
VTE + all-cause mortality 
40 mg qd     37.7 (33.5-41.9) 
 
 
Major bleeding 
40 mg qd     1.3 (0.6-2.4) 
Discontinuation 
Dabigatran 150 mg    3.7% 
Dabigatran 220 mg    3.7% 
Enoxaparin 40 mg     4.6% 
Acute coronary events 
Dabigatran 150 mg   1.0% 
Dabigatran 220 mg   0.4% 
Enoxaparin 40 mg    0.6% 
~Therapy length 6-10 days 
~Enoxaparin started pre-operatively 
in most patients, while dabigatran 
was started post-operatively 
 
 
 
RE-NOVATE36/  
VTE prophylaxis 
following THR 
VTE + all-cause mortality 
150 mg qd       8.6 (6.7-10.4) 
220 mg qd       6.0 (4.5-7.6) 
 
Major bleeding 
150 mg qd       1.3 (0.7-2.1) 
220 mg qd       2.0 (1.3-3.0) 
VTE + all-cause mortality 
40 mg qd      6.7 (5.1-8.3) 
 
 
Major bleeding 
40 mg qd      1.6 (0.9-2.5) 
 
Serious adverse events 
Dabigatran 150 mg    8% 
Dabigatran 220 mg    8% 
Enoxaparin 40 mg     7% 
Acute coronary events 
Dabigatran 150 mg    0.7% 
Dabigatran 220 mg    0.4% 
Enoxaparin 40 mg     0.8% 
~Therapy length 28-35 days 
~Enoxaparin started pre-operatively 
in most patients, while dabigatran 
was started post-operatively 
 
 
 
RE-MOBILIZE37/ 
VTE prophylaxis 
following TKR 
VTE + all-cause mortality 
150 mg qd      33.7 
220 mg qd      31.1  
 
Major bleeding 
150 mg qd      0.6 
220 mg qd      0.6 
VTE + all-cause mortality 
30 mg bid    25.3  
 
 
Major bleeding 
30 mg bid    1.4 
Serious adverse events 
Dabigatran 150 mg    6.5% 
Dabigatran 220 mg    6.9% 
Enoxaparin 30 mg     5.2% 
Cardiac events 
Dabigatran 150 mg    0.1% 
Dabigatran 220 mg    0.1% 
Enoxaparin 30 mg     0.1% 
~Therapy length 12-15 days 
~Enoxaparin or dabigatran started 
post-operatively in all patients 
~Confidence intervals not given for 
clinical outcomes 
 
 
 
STUDY/SETTING DABIGATRAN OUTCOMES WARFARIN OUTCOMES ADVERSE EVENTS COMMENTS 
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Table 4 (continued). Summary of Outcomes 
ASA=aspirin; bid=twice daily; HR=hazard ratio; RR= relative risk; qd=once daily 
 
RE-COVER32/ 
Acute VTE therapy 
Recurrent VTE or VTE-death 
150 mg bid, therapy       2.4% 
Therapy + 30 days         2.7% 
 
Major + clinically relevant bleeding 
150 mg bid                     5.6%    
Recurrent VTE or VTE-death 
2.1 %; HR 1.10 (0.65-1.84) 
2.5%;  HR 1.05 (0.65-1.70) 
 
Major + clinically relevant bleeding 
8.8%; HR 0.63 (0.47-0.84) 
Serious adverse event 
Dabigatran 13.0% 
Warfarin     11.8%; P=0.43 
Discontinuation 
Dabigatran 9.0% 
Warfarin    6.8%; P=0.05 
Acute coronary syndrome 
Dabigatran 0.4% 
Warfarin     0.2%; P=0.73 
~Dabigatran patients had 
significantly lower total bleeding 
rates, but higher rate of GI 
bleeding 
 
PETRO28/  
Stroke prevention 
in atrial fibrillation 
Thromboembolic events 
50 mg bid         2 of 107 (1.9%) 
150 mg bid       0 of 169 
300 mg bid       0 of 169 
 
Major + clinically relevant bleeding 
50 mg bid         2 of 107 (1.9%) 
150 mg bid      13 of 169 (7.7%) 
300 mg bid      17 of 169 (10.1%) 
Thromboembolic events 
 0 of 70 (0%) 
 
 
 
Major + clinically relevant bleeding 
4 of 107 (5.7%) 
Discontinuation 
Dabigatran 50 mg bid 4.7% 
Dabigatran 150 mg bid 5.3% 
Dabigatran 300 mg bid 8.9% 
Warfarin  0% 
Acute coronary syndrome:  
Dabigatran 50 mg 0.9% 
Dabigatran 300 mg 0.6% 
All others 0% 
~Compared dabigatran ± ASA to 
warfarin alone. All major 
bleeding occurred in patients 
taking 300 mg dabigatran + 
ASA.   
~All participants on adjusted-
dose warfarin prior to starting 
study 
Yamaguchi40/ 
Stroke prevention 
in atrial fibrillation 
Thromboembolic events 
Only one reported, occurred in post-
treatment period 
 
Major + clinically relevant bleeding 
110 mg bid   2 of 46 (4.3%) 
150 mg bid   5 of 58 (8.6%) 
Thromboembolic events 
1 of 62 (1.6%) 
 
 
Major + clinically relevant bleeding 
7 of 62 (11.3%) 
None reported  ~Unpublished study with 
minimal analysis provided 
RE-LY33/ 
Stroke prevention 
in atrial fibrillation 
Stroke or systemic embolism 
110 mg  bid  1.53%/year 
150 mg bid   1.11%/year 
 
Major bleeding 
110 mg bid   2.71%/year 
150 mg bid   3.11%/year 
Stroke or systemic embolism 
1.69%/year; RR 0.91 (0.74-1.11) 
                     RR 0.66 (0.53-0.82) 
 
Major bleeding 
3.36%/year; RR 0.80 (0.69-0.93) 
                     RR 0.93 (0.81-1.07) 
Discontinuation at 2 years 
Dabigatran 110 mg       21% 
Dabigatran 150 mg       21% 
Warfarin                       17% 
Myocardial infarction 
Dabigatran 110 mg  0.72%/yr 
Dabigatran 150 mg  0.74%/yr 
Warfarin                   0.53%/yr 
~Relative risk of MI with 
dabigatran 150 mg was 1.38 
compared to warfarin (95% 
CI,1.00-1.91) 
~Rates of intracranial bleeding 
with both doses of dabigatran 
were significantly lower than 
with warfarin  
